These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 39080018)

  • 1. Population pharmacokinetic and exposure-toxicity analyses of nab-paclitaxel after pegylated recombinant human granulocyte colony-stimulating factor administration in patients with metastatic breast cancer.
    Yang D; Xu G; Ding H; Zhong L; Zhu J; Mi X; Xin W; Zhou T; Wang J; Fang L
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):523-534. PubMed ID: 39080018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
    Tsushima T; Kasai H; Tanigawara Y
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
    Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.
    Chen N; Li Y; Ye Y; Palmisano M; Chopra R; Zhou S
    J Clin Pharmacol; 2014 Oct; 54(10):1097-107. PubMed ID: 24719309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients.
    Borgå O; Lilienberg E; Bjermo H; Hansson F; Heldring N; Dediu R
    Adv Ther; 2019 Oct; 36(10):2825-2837. PubMed ID: 31432461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.
    Shin KH; Lim KS; Lee H; Jang IJ; Yu KS
    Invest New Drugs; 2014 Aug; 32(4):636-43. PubMed ID: 24468886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
    Shi YK; Liu P; Yang S; Han XH; He XH; Ai B; Qin Y; Li B; Huang DZ; Zhang CG; Sun Y
    Ai Zheng; 2006 Apr; 25(4):495-500. PubMed ID: 16613688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
    Papadopoulos KP; Egorin MJ; Huang M; Troxel AB; Kaufman E; Balmaceda CM; Vahdat LT; Hesdorffer CS
    Cancer Chemother Pharmacol; 2001; 47(1):45-50. PubMed ID: 11221961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
    Gardner ER; Dahut WL; Scripture CD; Jones J; Aragon-Ching JB; Desai N; Hawkins MJ; Sparreboom A; Figg WD
    Clin Cancer Res; 2008 Jul; 14(13):4200-5. PubMed ID: 18594000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.
    Fisherman JS; Cowan KH; Noone M; Denicoff A; Berg S; Poplack D; Balis F; Venzon D; McCabe M; Goldspiel B; Chow C; Ognibene FP; O'Shaughnessy J
    J Clin Oncol; 1996 Mar; 14(3):774-82. PubMed ID: 8622023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Exposure-Response Analysis of nab-Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
    Li Y; Kassir N; Chen N; Wang X; Palmisano M; Zhou S
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):115-130. PubMed ID: 32459889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
    Ando M; Yonemori K; Katsumata N; Shimizu C; Hirata T; Yamamoto H; Hashimoto K; Yunokawa M; Tamura K; Fujiwara Y
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):457-65. PubMed ID: 21853310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
    Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose pegylated recombinant human granulocyte-colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open-label, randomized, non-inferiority trial.
    Yang S; Chen SS; Zhang CG; Zhou YL; Xiu M; Zhang P
    Br J Clin Pharmacol; 2024 Oct; 90(10):2621-2629. PubMed ID: 38925586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
    Cristea MC; Frankel P; Synold T; Rivkin S; Lim D; Chung V; Chao J; Wakabayashi M; Paz B; Han E; Lin P; Leong L; Hakim A; Carroll M; Prakash N; Dellinger T; Park M; Morgan RJ
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):589-598. PubMed ID: 30623229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Albumin-bound paclitaxel: a next-generation taxane.
    Gradishar WJ
    Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
    Huizing MT; Vermorken JB; Rosing H; ten Bokkel Huinink WW; Mandjes I; Pinedo HM; Beijnen JH
    Ann Oncol; 1995 Sep; 6(7):699-704. PubMed ID: 8664192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of paclitaxel protein-bound particles in patients with breast cancer: determining total and unbound paclitaxel in plasma by rapid equilibrium dialysis and liquid chromatography-tandem mass spectrometry.
    Li J; Li W; Dai X; Zhong D; Ding Y; Chen X
    Drug Des Devel Ther; 2019; 13():1739-1749. PubMed ID: 31190752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.